Chronic wounds include, but are not limited to, diabetic foot ulcers, venous leg ulcers, and pressure ulcers. They are a challenge to wound care professionals and consume a great deal of healthcare resources around the globe. They impact nearly 15% of Medicare beneficiaries and roughly 1-2% of the population in developed countries. Patients with nonhealing wounds are likely to be older adults, non-ambulatory or paralyzed, unable to provide self-care, and/or suffering from dementia. These ulcers last on average 12 to 13 months, recur in up to 60% to 70% of patients, can lead to loss of function and decreased quality of life, and are a significant cause of morbidity.
Predominantly a condition of the elderly, chronic wounds are becoming more prevalent and more difficult to treat and are associated with high treatment costs, representing an annual Medicare cost of at least $28 billion.
New therapies are needed to overcome the factors that contribute to delayed healing to provide a comprehensive approach to wound care and the treatment of chronic wounds. Krystal Biotech is using its STAR-D technology to develop a therapy to address this unmet need.